Pfizer Inc. (PFE)
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
Novo Nordisk is raking in billions from Ozempic and Wegovy. Pfizer wants in on the action, so it's teaming up with a biotech.
2 Beaten-Down Growth Stocks to Buy Without Hesitation in the 2024 Bull Market
Healthcare and beauty are both explosive industries -- and potential hunting grounds for good stocks. Pfizer is navigating the aftermath of its pandemic successes, but a much brighter future could be just ahead.
Pfizer: Seriously Undervalued At Peak Pessimism
Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the company announced promising results from a Phase 2 clinical trial, again demonstrating the clinical benefit of Elrexfio in the treatment of relapsed or refractory multiple.
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks
AT&T's dividend hasn't risen in a while due to a heavy debt load, but there could be plenty of progress in the years ahead. With a dividend yield above 10% at recent prices, PennantPark Floating Rate Capital can produce market-beating gains by holding its monthly payment steady over the long run.
Investing for the Next 12 Months? Buy These
If investors expect interest rates to hold until next year, they should consider dividend-yielding stocks like Altria (NYSE: MO), Bristol Myers, and Pfizer (NYSE: PFE), which offer reasonable values and attractive yields.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
High-yield dividend stocks can be potent long-term value creators. Pharma titans Pfizer and Bristol Myers Squibb sport two of the highest yields within their peer group.
Pfizer Stock: The Reversal Should Keep Going
Pfizer's stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term. The Company's Q1 results showed strong performance in non-COVID products and cost-saving measures, leading to analyst sentiment improvement. The recent Wall Street earnings estimates indicate that the Street expects PFE to bottom out in FY2024 in terms of EPS and that fundamentals will then rebound.
